drugset / Trial / NCT05405192
Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see if Dostarlimab is an effective treatment for Gestational Trophoblastic Neoplasia (GTN).
Timeline
- Start
- 2023-03-01
- Primary completion
- 2026-12-01
- Completion
- 2028-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dostarlimab | Monoclonal antibody | 1000 mg | Intravenous |